



# AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
CIN: L85190PB2010PLC040162

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Date: 02/08/2021

Dear Sir / Madam,

**Subject: Outcome of the Board Meeting held on August 02, 2021, Monday, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Monday, August 02, 2021 at 11.30 a.m concluded at 01 40 p.m. Following transactions were considered and approved:

1. Un-Audited Financial Results for the quarter ended on 30th June 2021.
2. The Board has considered and approved the offer and issue of fully paid-up equity shares of the Company, on a rights issue to existing eligible equity shareholders of the Company as at the record date for an amount not exceeding Rs. 30.00 Crore, in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the "Rights Issue").  
For the purposes of giving effect to the Rights Issue, the Board has constituted and authorized the Right Issue Committee to decide the terms and conditions of the Rights Issue, including the instrument, issue price, rights entitlement ratio, record date, timing of the Rights Issue and other related matters.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,

Yours Truly,

**For Ajooni Biotech Limited**

  
**Jasjit Singh**  
Managing Director  
DIN: 01937631



# AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
CIN: L85190PB2010PLC040162

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Date: 02/08/2021

Dear Sir / Madam,

**SYMBOL: AJOONI**

**Sub.: Approval of Un-audited Financial Results for the quarter ended 30<sup>th</sup> June, 2021.**

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 02/08/2021 at the Registered Office of the company have considered and approved the Audited Financial Statements for the quarter ended 30th June, 2021. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended on 30th June 2021.
2. Limited Review Report from the auditor for the quarter ended on 30th June 2021.

You are requested to kindly take the same on record.

Thanking You,

Yours Truly,

For Ajooni Biotech Limited

Jasjot Singh  
Managing Director

DIN: 01937631



**AJOONI BIOTECH LIMITED**

CIN : L85190PB2010PLC040162

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021 (In Lakhs)**

PARTICULARS	Quarter Ended			Year Ended (Audited)
	30.06.2021	31.03.2021	30.06.2020	
<b>I Income</b>				31.03.2021
Revenue from operations	1,584.62	1,618.80	983.16	30.06.2020
Other income	0.92	0.52	0.51	30.06.2021
<b>Total income from operations</b>	<b>1,585.54</b>	<b>1,619.32</b>	<b>983.67</b>	<b>1,585.54</b>
<b>II Expenses</b>				
Cost of Material Consumed	1,342.82	1,395.36	815.32	815.32
Change In Inventories	(1.49)	(22.74)	(4.03)	(1.49)
Employee benefit expenses	38.10	29.65	32.05	38.10
Finance costs	13.30	15.12	10.44	13.30
Depreciation and amortization expenses	18.93	14.44	15.50	18.93
Payment to NSE				15.50
Other expenses	133.08	182.59	70.61	133.08
<b>Total expenses</b>	<b>1,544.74</b>	<b>1,614.42</b>	<b>939.89</b>	<b>1,544.74</b>
<b>III Profits/(Loss) before exceptional items and tax</b>	<b>40.80</b>	<b>4.90</b>	<b>43.78</b>	<b>40.80</b>
<b>IV Exceptional items</b>				
<b>V Profits/(Loss) before tax</b>	<b>40.80</b>	<b>4.90</b>	<b>43.78</b>	<b>40.80</b>
<b>V1 Tax expenses</b>				
a) Current tax	10.50	1.43	13.60	10.50
b) Deferred tax	1.05	0.95	-	1.05
b) Mar Credit	-	-	-	0
<b>VII Net Profit/(Loss) for the period/year</b>	<b>31.35</b>	<b>4.42</b>	<b>30.18</b>	<b>31.35</b>
<b>VIII Other comprehensive income (net of tax)</b>				
Items that will not be reclassified to profit or loss:		(45)		
<b>Total other comprehensive income</b>		(45)		(181)
<b>IX Total comprehensive income for the period/year (VII+VIII)</b>	<b>31.35</b>	<b>(40.83)</b>	<b>30.18</b>	<b>31.35</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>1,000.55</b>	<b>1,000.55</b>	<b>840.50</b>	<b>1,000.55</b>
<b>XI Other equity (excluding revaluation reserve)</b>	<b>596.69</b>	<b>564.51</b>	<b>748.60</b>	<b>596.69</b>
<b>XII EPS in Rs. (Face Value of Rs.10/- each)*</b>				



7/10

-Basic	0.31	0.04	0.36	0.31	0.36	0.37
-Diluted	0.31	0.04	0.36	0.31	0.36	0.37

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 02.08.2021 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments", and therefore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.



For Ajoon Biotech Limited

Jasjot Singh

Managing Director

DIN:

01937631

Date: 02/08/2021

Place : Mohali

**AJOONI BIOTECH LIMITED**

CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities  
For the Year ended on 30th June 2021

in Rs.

PARTICULARS	30TH JUNE 2021	31ST MARCH 2021
<b>I. ASSETS</b>		
<b>(1) Non - Current Assets</b>		
a) Property, Plant and Equipment	51,705,299	51,617,081
b) Financial Assets		
(1) Non-Current Investments	11,316,761	11,482,856
(2) Advances		
c) Deffered Tax Asset	1,570,029	1,465,029
d) Other Non Current Assets	1,055,272	1,407,030
<b>(2) Current Assets</b>		
a) Inventories	53,504,349	53,762,090
b) Financial Assets		
(1) Cash & Cash Equivalent	17,165,795	2,440,976
(2) Short Term Loans and advances	19,912,284	19,882,931
(3) Trade Receivables	137,270,404	137,117,389
c) Other Current Asset	1,087,547	1,087,547
<b>TOTAL Rs.</b>	<b>294,587,741</b>	<b>280,262,930</b>

**II EQUITY AND LIABILITIES**

<b>(1) Equity</b>		
a) Equity Share Capital	100,055,820	100,055,820
b) Other Equity	59,669,125	56,451,410
<b>(2) Non-Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	22,766,076	18,979,313
<b>(3) Current Liabilities</b>		
a) Financial Liabilities		
(1) Borrowings	54,472,542	48,857,260
(2) Trade Payables	54,848,078	54,003,957
b) Other Current Liabilities	1,726,100	411,890
c) Current tax liabilities (Net)	1,050,000	1,503,280
<b>TOTAL Rs.</b>	<b>294,587,741</b>	<b>280,262,930</b>

Date: 02.08.2021

Place: Mohali

For Ajooni Biotech Limited

Jasjot Singh

Managing Director

DIN: 01937631



# Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

( A PEER REVIEWED FIRM )

## Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30<sup>th</sup> June 2021 (“the Statement”) attached herewith ,being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to “Review of Interim Financial Information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (‘ Ind AS’) prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.  
Chartered Accountants

CA Konia Madan  
Partner

M.No 547759

Date: 02-08-2021

UDIN: 21547759AAAAAW4351

House No. 1122, Sector 71, Mohali

Mobile :096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com